A beta-arrestin 2 signaling complex mediates lithium action on behavior.

Area of Science:

• Neuropharmacology
• Molecular and Cellular Neuroscience
• GPCR Signaling

Background:

• Beta-arrestins (beta-arrestin 1 and 2) are known to mediate G protein-coupled receptor (GPCR) desensitization.
• Beta-arrestins also facilitate GPCR signaling independently of G proteins by forming distinct signaling complexes.
• Lithium is a widely used medication for psychiatric disorders, including bipolar disorder, schizophrenia, and depression.

Purpose of the Study:

• To investigate the role of beta-arrestin 2 in lithium's regulation of Akt/glycogen synthase kinase 3 (GSK3) signaling.
• To determine if lithium's behavioral effects in mice are dependent on beta-arrestin 2-mediated signaling complexes.

Main Methods:

• Administration of lithium to wild-type and beta-arrestin 2 knockout mice.
• Analysis of Akt/GSK3 signaling pathways.
• Behavioral assessments in mice.

Main Results:

• Lithium disrupted a signaling complex comprising Akt, beta-arrestin 2, and protein phosphatase 2A in wild-type mice.
• Lithium administration failed to alter Akt/GSK3 signaling or induce behavioral changes in beta-arrestin 2 knockout mice.
• These findings indicate that beta-arrestin 2 is crucial for lithium's effects on these signaling pathways and behaviors.

Conclusions:

• Beta-arrestin 2 mediates lithium's effects on Akt/GSK3 signaling and associated behaviors.
• Lithium disrupts beta-arrestin 2-dependent signaling complexes, offering a novel mechanism for its therapeutic actions.
• Targeting the formation of beta-arrestin-mediated signaling complexes presents a potential pharmacological strategy for modulating GPCR function.